Infliximab biosimilar CT‐P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2133|177|6|e325-e326

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.177, Iss.6, 2017-12, pp. : e325-e326

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Clinical experience with infliximab biosimilar in psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : e347-e348

John Wiley & Sons Inc

Access to resources Recommend Favorite

Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 6, 2015-06 ,pp. : 1613-1620

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adalimumab in the treatment of moderate‐to‐severe chronic plaque psoriasis in patients switching from other biologics

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 9, 2015-09 ,pp. : 1742-1749

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Review of the Treatment of Psoriasis with Infliximab

By  

Reviews on Recent Clinical Trials, Vol. 1, Iss. 3, 2006-09 ,pp. : 201-205

Bentham Science Publishers

Access to resources Recommend Favorite

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trials

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 949-961

John Wiley & Sons Inc

Access to resources Recommend Favorite